A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Arcus Biosciences, Inc.
City of Hope Medical Center
Incyte Corporation
Toray Industries, Inc
M.D. Anderson Cancer Center
ImmunityBio, Inc.
AstraZeneca
Endocyte
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center